Treatment of pyoderma gangrenosum with intravenous immunoglobulin.
BACKGROUND
Intravenous immunoglobulin (IVIG) is increasingly being used to treat inflammatory and autoimmune disease.


OBJECTIVE
To elucidate the efficacy of IVIG as an adjunct treatment for pyoderma gangrenosum (PG).


METHODS
Ten patients with PG were treated with IVIG at Johns Hopkins Department of Dermatology. All patients had severe mutilating and/or refractory disease requiring multi-agent therapy. The charts were reviewed retrospectively.


RESULTS
Seven of the ten patients had clearance of PG lesions in the setting of IVIG and six of these patients maintained efficacy with repeated IVIG treatment. Five patients complained of nausea with treatment, and in one case nausea was severe and intractable. One patient developed an immune reaction requiring diphenhydramine and methylprednisolone and another experienced aseptic meningitis.


CONCLUSIONS
IVIG may be an effective adjuvant in the treatment of PG and has an acceptable side-effect profile. Randomized, placebo-controlled, double-blinded trials are needed to confirm this hypothesis.
Cummins
D L
DL
Department of Dermatology, Johns Hopkins Medical Institutions, 601 North Caroline Street, Suite 6042, Baltimore, MD 21287, USA.
Anhalt
G J
GJ
Monahan
T
T
Meyerle
J H
JH
D000293:Adolescent; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010502:Perineum; D017511:Pyoderma Gangrenosum / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous